白介素-6在多发性大动脉炎中的研究现状与进展

Current status and progress of interleukin-6 in Takayasu arteritis

目的 总结白介素-6(interleukin-6,IL-6)在多发性大动脉炎(Takayasu arteritis,TAK)中的研究现状与进展。方法 查阅国内外IL-6在TAK中相关研究的文献,对IL-6在TAK中的研究进展进行总结。结果 IL-6是由多种细胞分泌的一种促炎症细胞因子,参与了多种炎症与免疫反应,并在TAK的进展中发挥重要作用。IL-6在TAK患者外周血及血管壁组织中表达水平升高,IL-6的基因多态性与TAK的发生可能存在一定的相关性,IL-6受体拮抗剂托珠单抗治疗TAK具有一定的有效性与安全性。结论 IL-6可作为TAK活动期与复发的监测指标之一,IL-6受体拮抗剂可作为TAK的治疗选择,但它在TAK不同阶段的应用结果仍值得期待。

Objective To summarize the research status and progress of interleukin-6(IL-6)in Takayasu arteritis(TAK).Method Recent literature published at home and abroad about the study of IL-6 in the TAK was reviewed and analyzed.Results IL-6 was a pro-inflammatory cytokine secreted by a variety of cells,which participated in a variety of inflammatory and immune reactions,and played an important role in the progress of TAK.The expression levels of IL-6 in the peripheral blood and vascular wall tissues of patients with TAK were increased.The gene polymorphism of IL-6 might be related to the occurrence of TAK.Tocilizumab,an IL-6 receptor antagonist,was effective and safe in the treatment of TAK.Conclusions IL-6 can be used as one of the monitoring indicators for the active phase and recurrence of TAK.IL-6 receptor antagonist can be used as the treatment choice of TAK,but the application results in different stages of TAK are still worth expecting.